Literature DB >> 27660262

Serum Markers of Neurodegeneration in Maple Syrup Urine Disease.

Giselli Scaini1, Tássia Tonon2, Carolina F Moura de Souza3, Patricia F Schuk4, Gustavo C Ferreira5, Joao Seda Neto6, Tatiana Amorin7, Ida Vanessa D Schwartz2,3, Emilio L Streck8.   

Abstract

Maple syrup urine disease (MSUD) is an inherited disorder caused by deficient activity of the branched-chain α-keto acid dehydrogenase complex involved in the degradation pathway of branched-chain amino acids (BCAAs) and their respective α-keto-acids. Patients affected by MSUD present severe neurological symptoms and brain abnormalities, whose pathophysiology is poorly known. However, preclinical studies have suggested alterations in markers involved with neurodegeneration. Because there are no studies in the literature that report the neurodegenerative markers in MSUD patients, the present study evaluated neurodegenerative markers (brain-derived neurotrophic factor (BDNF), cathepsin D, neural cell adhesion molecule (NCAM), plasminogen activator inhibitor-1 total (PAI-1 (total)), platelet-derived growth factor AA (PDGF-AA), PDGF-AB/BB) in plasma from 10 MSUD patients during dietary treatment. Our results showed a significant decrease in BDNF and PDGF-AA levels in MSUD patients. On the other hand, NCAM and cathepsin D levels were significantly greater in MSUD patients compared to the control group, while no significant changes were observed in the levels of PAI-1 (total) and PDGF-AB/BB between the control and MSUD groups. Our data show that MSUD patients present alterations in proteins involved in the neurodegenerative process. Thus, the present findings corroborate previous studies that demonstrated that neurotrophic factors and lysosomal proteases may contribute, along with other mechanisms, to the intellectual deficit and neurodegeneration observed in MSUD.

Entities:  

Keywords:  Brain-derived neurotrophic factor (BDNF); Cathepsin D; Maple syrup urine disease; Neural cell adhesion molecule (NCAM); Neurodegeneration; Platelet-derived growth factor AA (PDGF-AA)

Mesh:

Substances:

Year:  2016        PMID: 27660262     DOI: 10.1007/s12035-016-0116-8

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  112 in total

Review 1.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 2.  Zippers make signals: NCAM-mediated molecular interactions and signal transduction.

Authors:  Peter S Walmod; Kateryna Kolkova; Vladimir Berezin; Elisabeth Bock
Journal:  Neurochem Res       Date:  2004-11       Impact factor: 3.996

3.  Antisense inhibition of acetylcholinesterase gene expression for treating cognition deficit in Alzheimer's disease model mice.

Authors:  Ai-Ling Fu; Xing-Mei Zhang; Man-Ji Sun
Journal:  Brain Res       Date:  2005-12-09       Impact factor: 3.252

Review 4.  NCAM in neuropsychiatric and neurodegenerative disorders.

Authors:  Leann H Brennaman; Patricia F Maness
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

5.  The role of conceptual frameworks in epidemiological analysis: a hierarchical approach.

Authors:  C G Victora; S R Huttly; S C Fuchs; M T Olinto
Journal:  Int J Epidemiol       Date:  1997-02       Impact factor: 7.196

6.  Acute Administration of Branched-Chain Amino Acids Increases the Pro-BDNF/Total-BDNF Ratio in the Rat Brain.

Authors:  Giselli Scaini; Meline O S Morais; Camila B Furlanetto; Luiza W Kist; Talita C B Pereira; Patrícia F Schuck; Gustavo C Ferreira; Matheus A B Pasquali; Daniel P Gelain; José Cláudio F Moreira; Maurício R Bogo; Emilio L Streck
Journal:  Neurochem Res       Date:  2015-02-14       Impact factor: 3.996

7.  Neurocognitive profile in a case of maple syrup urine disease.

Authors:  Karin S Walsh; Megan N Scott
Journal:  Clin Neuropsychol       Date:  2010-03-02       Impact factor: 3.535

8.  L-Carnitine supplementation decreases DNA damage in treated MSUD patients.

Authors:  Caroline Paula Mescka; Gilian Guerreiro; Tatiane Hammerschmidt; Jéssica Faverzani; Daniella de Moura Coelho; Vanusa Mandredini; Carlos Alberto Yasin Wayhs; Moacir Wajner; Carlos Severo Dutra-Filho; Carmen Regla Vargas
Journal:  Mutat Res       Date:  2015-03-28       Impact factor: 2.433

9.  Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease.

Authors:  M Narisawa-Saito; K Wakabayashi; S Tsuji; H Takahashi; H Nawa
Journal:  Neuroreport       Date:  1996-11-25       Impact factor: 1.837

Review 10.  Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond.

Authors:  Breno Satler Diniz; Antonio Lucio Teixeira
Journal:  Neuromolecular Med       Date:  2011-09-07       Impact factor: 3.843

View more
  8 in total

1.  Coadministration of tianeptine alters behavioral parameters and levels of neurotrophins in a chronic model of Maple Syrup Urine disease.

Authors:  Fábio A Morais; Isabela S Lemos; Rafaela T Matiola; Maria Luísa S Freitas; Carolina G Alano; Julia Cabral; Leticia B Wessler; Jaqueline S Generoso; Giselli Scaini; Gislaine Z Réus; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2022-04-08       Impact factor: 3.584

2.  Evaluation of plasma biomarkers of inflammation in patients with maple syrup urine disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuck; Gustavo C Ferreira; João Quevedo; João Seda Neto; Tatiana Amorim; Jose S Camelo; Ana Vitoria Barban Margutti; Rafael Hencke Tresbach; Fernanda Sperb-Ludwig; Raquel Boy; Paula F V de Medeiros; Ida Vanessa D Schwartz; Emilio Luiz Streck
Journal:  J Inherit Metab Dis       Date:  2018-05-08       Impact factor: 4.982

3.  Real-world management of maple syrup urine disease (MSUD) metabolic decompensations with branched chain amino acid-free formulas in France and Germany: A retrospective observational study.

Authors:  Pascale de Lonlay; Roland Posset; Ulrike Mütze; Karine Mention; Delphine Lamireau; Manuel Schiff; Aude Servais; Jean Baptiste Arnoux; Anaïs Brassier; Myriam Dao; Claire Douillard; Chris Ottolenghi; Clément Pontoizeau; Federica Miotto; Jeannie Le Mouhaër
Journal:  JIMD Rep       Date:  2021-03-06

4.  Exposure to leucine induces oxidative stress in the brain of zebrafish.

Authors:  Bianca Z de Medeiros; Leticia B Wessler; Mariane B Duarte; Isabela S Lemos; Gabriela Candiotto; Rafael O Canarim; Paulo C L Dos Santos; Carolina A Torres; Giselli Scaini; Eduardo P Rico; Jaqueline S Generoso; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2022-03-11       Impact factor: 3.584

Review 5.  Cathepsin D-Managing the Delicate Balance.

Authors:  Olja Mijanovic; Anastasiia I Petushkova; Ana Brankovic; Boris Turk; Anna B Solovieva; Angelina I Nikitkina; Sergey Bolevich; Peter S Timashev; Alessandro Parodi; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

Review 6.  Maple syrup urine disease: mechanisms and management.

Authors:  Patrick R Blackburn; Jennifer M Gass; Filippo Pinto E Vairo; Kristen M Farnham; Herjot K Atwal; Sarah Macklin; Eric W Klee; Paldeep S Atwal
Journal:  Appl Clin Genet       Date:  2017-09-06

7.  Discovery of Biomarker Panels for Neural Dysfunction in Inborn Errors of Amino Acid Metabolism.

Authors:  Alba-Aina Castells; Daniela Gueraldi; Rafel Balada; Alba Tristán-Noguero; Elisenda Cortès-Saladelafont; Federico Ramos; Silvia Meavilla; Mariela De Los Santos; Camila Garcia-Volpe; Roser Colomé; Maria Luz Couce; Cristina Sierra; Aida Ormazábal; Marta Batllori; Rafael Artuch; Judith Armstrong; Soledad Alcántara; Àngels Garcia-Cazorla
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

8.  Information and Diagnosis Networks - tools to improve diagnosis and treatment for patients with rare genetic diseases.

Authors:  Taiane Alves Vieira; Franciele Barbosa Trapp; Carolina Fischinger Moura de Souza; Lavínia Schuler Faccini; Laura Bannach Jardim; Ida Vanessa Doederlein Schwartz; Mariluce Riegel; Carmen Regla Vargas; Maira Graeff Burin; Sandra Leistner-Segal; Patrícia Ashton-Prolla; Roberto Giugliani
Journal:  Genet Mol Biol       Date:  2019-06-10       Impact factor: 1.771

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.